This is why we suggest MCL1/1p12 ratio ≥ 2.0 and/or average MCL1 gene count per tumor cell ≥ 5.0 as reasonable selection criteria for potential targeted treatments since these criteria reflect the highest unequivocal amplification level based on our data from a larger series of adult and pediatric PBs. Here, MCL1 is linked to neoplasm.